Короткий опис (реферат):
Nowadays bronchial asthma (BA) is one of the leading problems along with cardiovascular and infectious diseases. The GINA edition of 2017 states that non-rational use of BASD drugs is a risk factor for acute asthma, and their excessive use is a risk factor for premature death from the disease itself. We examined 75 patients with a diagnosis of asthma. By the study design, all patients had EBW or obesity and the mean body mass index (BMI) in the examined patients was 31.76 kg / m2. the patients in the main group on an average lowered the body weight by 4.5 kg, and BMI from 32.00 kg / m2 changed by 29.7 kg / m2 (p˂0.05). We observed a significant decrease in the T- and B-lymphocyte and CIC in patients of the main group (p<0.05), however, 32 weeks after the use of TPC, it was noted that the immunograms returned to the baseline. patients in the main group had significantly better control of asthma than patients in the comparison and control groups (p˂0.05). Also, attention should be attracted to the fact that the given figure shows average values for all severity courses of BA, that is, the group includes patients with mild to moderate and severe course of asthma. Thus, we found that 78% of patients in the main group with mild asthma got control of the disease during treatment and kept it for 32 weeks. After 32 weeks of the follow-up, the patients began to notice a decrease in asthma control, which was reflected in the results of the AST test, so in our opinion, it is rational to use the drug for 6 to 9 months. The patients with asthma against the background of EBW or obesity have alternative ways to solve the problem of asthma control, namely, studying in asthma school against the background of pharmacological correction drugs bacterial lysate and inosine promobas (RRR = 0.75, NNT = 2.12).
